Planning approval accelerates London Cancer Hub expansion, unlocking construction opportunities across UK life sciences infrastructure growth.
Planning consent for the £1 billion expansion of the London Cancer Hub in Sutton marks a major step for UK science infrastructure and the digital construction sector supporting advanced research environments. Led by Aviva Capital Partners and development manager Socius, the approved scheme will deliver around one million square feet of laboratory and research space, creating capacity for collaboration between academic institutions, healthcare providers, and life sciences companies.
Granted by Sutton Council on World Cancer Day, the decision advances delivery of facilities designed to support cancer research, treatment development, and life sciences commercialisation while generating employment and investment across the UK.
Strengthen UK life sciences infrastructure
The London Cancer Hub is recognised as nationally significant science infrastructure, supporting government ambitions to position the UK as a global centre for life sciences innovation. The approved expansion covers 12 acres and will provide laboratories, research facilities, and innovation spaces supporting collaboration between researchers, clinicians, start-ups, and global life sciences firms.
Once the wider district is complete, the development is expected to support around 13,000 jobs and contribute an estimated £1.2 billion in Gross Value Added to the UK economy, according to analysis by the London Borough of Sutton. The next construction phase alone is forecast to generate around 3,000 new jobs, mainly within high-skilled research and life sciences manufacturing.
The district already hosts The Institute of Cancer Research (ICR), The Royal Marsden NHS Foundation Trust, and the Innovation Gateway, forming a cluster focused on cancer research, treatment and commercialisation.
Research facilities
The expansion also presents significant opportunities for the digital construction sector delivering laboratory and life sciences facilities. Complex research environments demand advanced digital design, Building Information Modelling (BIM), precision engineering coordination, and sustainable construction approaches aligned with net-zero carbon targets.
Designed by Gensler, with Arup providing structural engineering and Savills advising on planning, the masterplan integrates research buildings with public spaces and amenities, including approximately 220 affordable homes for key workers. The scheme targets net-zero carbon in operation while creating a district supporting collaboration and workforce wellbeing.
The project received the New London Architecture Award 2025 for Healthcare and Life Sciences, recognising its mixed-use science district model that combines laboratories, workplaces, and community spaces.
Investment catalyst for innovation
Industry leaders describe the project as a catalyst for private investment and scientific collaboration, strengthening London’s position in global health research.
Sophie White, Sector Head Regeneration at Aviva Capital Partners, said: “We’re delighted to secure planning consent for the London Cancer Hub, a landmark moment for this scheme. This development will deliver critical science infrastructure for the UK, helping the UK get ready for the future by creating an environment where innovation can flourish and lifesaving research can accelerate. We are proud to play a role in shaping a campus that will have a profound impact on global health, as well as the economy.”
Daniel May, Director of Socius, added: “The London Cancer Hub is about more than buildings. We are delivering the next phase of investment into an already world-class cancer district, creating a powerful catalyst for private investment and long-term growth. It’s about creating a vibrant ecosystem where collaboration drives discovery. By working closely with the ICR, The Royal Marsden, and our partners, we are delivering a worldclass environment that will support businesses, attract investment, and ultimately improve patient outcomes.”
Planning consent welcomed
Research and healthcare partners view the expansion as essential for translating discoveries into patient treatments.
Professor Kristian Helin, Chief Executive of The Institute of Cancer Research, said: “We warmly welcome the approval of these ambitious new plans for The London Cancer Hub, a project the ICR has long championed. Their delivery will create a vibrant, globally competitive life-sciences facility at our Sutton campus, attracting innovative companies and deepening collaboration between academia, industry and the NHS… Overall, these plans will accelerate the translation of pioneering discoveries into patient benefit and establish The London Cancer Hub as a nationally and internationally significant centre for cancer innovation.”
Dame Cally Palmer, Chief Executive of The Royal Marsden NHS Foundation Trust, added: “A world leading partnership already exists between The Royal Marsden and the Institute of Cancer Research… Partnering with life sciences and Aviva through the London Cancer Hub will have a major impact and benefit for the local community, the country, and for our international collaborations in cancer research.”
Read next: Opportunities in €500bn German infrastructure – Build in Digital
Are you a building professional? Sign up for a FREE MEMBERSHIP to upload news stories, post job vacancies, and connect with colleagues on our secure social feed.
